Background: Over 400,000 Australians are affected by diabetic kidney disease. Current clinical therapies only delay the progression to end stage renal disease and thus new therapies are urgently required. The main aim of our group is to understand why people develop complications from diabetes, and the mechanisms responsible for those complications, in the hope of finding new therapeutic targets that can halt progression to end stage renal disease. The complement cascade is a highly sophisticated network of immune proteins that are activated in response to invading pathogens or tissue injury. Under normal conditions complement is tightly regulated by a number of fluid-phase and cell surface proteins; however, when complement is hyperactivated it drives a severe inflammatory response. Complement comprises four key pathways that all result in the formation of C5a, a major effector molecule which, via ligation with its receptor C5aR1, initiates pathology in a number of inflammatory diseases. Previous studies have suggested that the complement system may be involved in the pathophysiology of diabetic kidney disease, though the role of specific complement pathways in the development of this disease remains incompletely defined. The aim of this study is to define the predominant complement cascade activated in human diabetic kidney disease using a mass spectrometry proteomics-based approach and to assess if complement activation products can serve as biomarkers for patients with diabetes at risk of progression to end stage renal disease. Project related methods/skills/technologies: • Western immunoblotting, ELISA and immunohistochemistry. • Proteomics (LC-MS/MS). This study is being offered as an Honours project and would suit students interested in pathology and translational studies.
kidney, diabetes, pathology, medicine, clinical, complement, inflammation, physiology, pharmacology, microbiology, anatomy, developmental biology, molecular biology, biochemistry, immunology, human pathology, clinical, neuroscience
Central Clinical School » Diabetes
Top-up scholarship funding available
Alfred Research Alliance
Sih Min Tan